We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant. The hepatic enzyme disturbances normalized after discontinuation of pegvisomant. After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis. Clinicians should be aware of this potential severe adverse drug reaction and therefore frequent control of hepatic enzymes is mandatory during treatment with pegvisomant.

Additional Metadata
Persistent URL dx.doi.org/10.1530/eje.1.02160, hdl.handle.net/1765/56070
Journal European Journal of Endocrinology
Feenstra, J, van Aken, M.O, de Herder, W.W, Feelders, R.A, & van der Lely, A-J. (2006). Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant. European Journal of Endocrinology, 154(6), 805–806. doi:10.1530/eje.1.02160